Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Anteris Technologies has completed a US$320m capital raise, including a US$230m underwritten public offering and a US$90m strategic investment from Medtronic. The funding will support the global pivotal PARADIGM trial, manufacturing expansion, and research and development activities. The PARADIGM trial is evaluating the safety and effectiveness of DurAVR Transcatheter Heart Valve in patients with severe aortic stenosis.

Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios